tbuckley/cabot-search huggingface dataset:
SAT0418 Can the automated neuropsychological assessment metrics (ANAM) predict cognitive impairment compared to a comprehensive neuropsychological battery in patients with systemic lupus erythematosus (SLE)?
Authors: Z. Touma, D. Beaton, C. Tartaglia, L. Ruttan, S. Lombardi, J. Su, J. Wither, M. Fritzler, R. Green
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The diagnosis of cognitive impairment (CI) is often delayed requiring use of a comprehensive battery (CB). The Automated Neuropsychological Assessment Metrics (ANAM) is a computerised tool that can be used to screen for CI. <h3>Objectives</h3> To determine the ability of ANAM (v4) GNS Battery to predict CI in patients with systemic lupus erythematosus (SLE). <h3>Methods</h3> SLE patients (n=98), aged 18–65 years, attending a single centre between July 2016-April 2017 were recruited. Participants were administered the ANAM and CB on the same day. ANAM throughput scores were used to provide an estimate of cognitive efficiency. Patient scores on the ANAM and CB were compared to a normative sample of age and gender-matched healthy controls. The CB evaluates the following major cognitive domains: manual motor speed and dexterity, simple attention and processing speed, visual-spatial construction, verbal fluency, learning and memory (visuospatial and memory), and executive functioning (untimed and timed). ANAM evaluates the following major cognitive domains: attention and processing speed, memory, visual-spatial processing, executive functioning, abstract language function and fine motor processing. CI was operationalized on the CB and ANAM as a z-score of ≤−1.5 on≥2 domains or a z-score ≤−2.0 on≥1 domains, or either. The performance of ANAM was compared against the CB using different CI definitions. Descriptive analysis was used to determine prevalence, sensitivity (Sn), specificity (Sp), Positive Predictive Value (PPV) and Negative Predictive Value (NPV). <h3>Results</h3> Of the 98 patients (90.8% female), the mean age at SLE diagnosis was 28.5±10.2 and disease duration at enrolment was 15.5±10.0 years. Prevalence of CI using CB ranged between 40.0%–44.8% (z≤−1.5 in≥2 domains and z≤−2.0 in≥1 domains, respectively) and 55.2% for either. Prevalence of CI using the ANAM ranged between 30.8%–39.3%% (z≤−1.5 in≥2 domains and z≤−2.0 in≥1 domains, respectively) and 43.0% for either. ANAM Sn/Sp was 52/73% and PPV/NPV was 70/55% [based on z≤−1.5 in≥2 domains or z≤−2.0 in≥1 domains for ANAM and CB (corresponding for A+B and E+F in table 1)]. <h3>Conclusions</h3> ANAM is a promising tool for the assessment of CI in SLE. Future studies are required to determine if the sensitivity of the ANAM can be improved against the current CB. <h3>Disclosure of Interest</h3> None declared
THU0161 Trends in the incidence of amyloidosis in patients with rheumatoid arthritis in spain: an observational cohort study of hospital discharges from 1999 to 2015 (TREND-AR STUDY)
Authors: J.L. Morell Hita, R. Mazzucchelli, E. Perez Fernandez, J. Quiros, C. Macía Villa, N. Crespi, M. Peña, C. Barbadillo, M. Espinosa, H. Godoy, M. Fernandez Prada, M. Galindo, A. Garcia Vadillo, O. Guzon Illescas, A. Herranz, C. Martinez Prada, C. Morado Quiñoa, V. Villaverde
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Treatment and evolution of Rheumatoid Arthritis (RA) have had an important change in the last years. However the trend of amyloidosis, habitually related to long-standing and active RA, in Spain is unknown. <h3>Objectives</h3> To analyse the incidence and trend of hospital admissions for amyloidosis in RA patients in Spain from 1999 to 2015. <h3>Methods</h3> We performed an observational retrospective population study analysing the spanish administrative database that includes a Minimun Basic Data Set (MBDS) of hospital admissions of RA patients from 1999 to 2015. We selected the MBDSs for amyloidosis. Cases were identified by the presence in primary and secondary diagnosis of its ICD9 code. The population at risk was estimated with an estimated prevalence of RA of 0,5% (0,8% women and 0,2% men). Crude and adjusted rates were calculated, and the trend was analysed using the Generalised Linear Model (GLM) with the year as the analysis variable. SPSS version 20 (SPSS Inc, Chicago, IL) was used. <h3>Results</h3> 338.343 RA hospital admissions were detected, being 3085 (0,9%) due to amyloidosis with 2298 (74,5%) women and 787 (25,5%) men. Mean age 65,42 (SD 13,08). There were 366 (11,9%) deaths. Age-adjusted rate during the period was 122,87/10<sup>5</sup> inhab. per year (98,96 women and 146,79 men). Amyloidosis age-adjusted rate decreased from 138,88/10<sup>5</sup> inhab. per year in 1999 to 71,47 in 2015, both women (128,18 in 1999 to 61,35 in 2015) and men (162,36 in 1999 to 107,95 in 2015). An annual decrease in the amyloidosis rate of 4,6% is estimated (RRI 0,953; CI 95% 0,939–0,968). <h3>Conclusions</h3> In Spain from 1999 to 2015 amyloidosis hospital admissions in patients with RA decreased, with an estimation of 4,6% annual reduction. This finding concurs with a greater knowledge of RA and its treatment advances with ”treat-to-target” strategies. <h3>Disclosure of Interest</h3> None declared
Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders
Authors: Jerold Chun, Yasuyuki Kihara, Deepa Jonnalagadda, Victoria A. Blaho
Journal: The Annual Review of Pharmacology and Toxicology (2019)

Fingolimod (FTY720, Gilenya) was the first US Food and Drug Administration-approved oral therapy for relapsing forms of multiple sclerosis (MS). Research on modified fungal metabolites converged with basic science studies that had identified lysophospholipid (LP) sphingosine 1-phosphate (S1P) receptors, providing mechanistic insights on fingolimod while validating LP receptors as drug targets. Mechanism of action (MOA) studies identified receptor-mediated processes involving the immune system and the central nervous system (CNS). These dual actions represent a more general theme for S1P and likely other LP receptor modulators. Fingolimod's direct CNS activities likely contribute to its efficacy in MS, with particular relevance to treating progressive disease stages and forms that involve neurodegeneration. The evolving understanding of fingolimod's MOA has provided strategies for developing next-generation compounds with superior attributes, suggesting new ways to target S1P as well as other LP receptor modulators for novel therapeutics in the CNS and other organ systems.
FRI0204 Radiographic progression of spondyloartritis patients after 13 years of follow up: data from the regisponser database
Authors: L. Pérez Sánchez, P. Font, C. López, L. Bautista, L. Ladehesa, I. Gómez, A. Escudero, E. Collantes, M.C. Castro
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To describe the radiographic evolution after 13 years of follow-up in a monographic consultation of patients with Axial Spondyloarthritis <b>(</b>EspAax) included in REGISPONSER at the Reina Sofía University Hospital in Córdoba. <h3>Methods</h3> Seventy eight SpA patients from the REGISPONSER registry were analysed in an observational study, which were evaluated for the first time in the year 2004–2005. The last x-rays analysis of the cervical and lumbar spine, pelvis and hips were recorded. Two independent observers evaluated the radiographs and calculated the BASRI index. The interobserver concordance was studied using Cohen's Kappa statistic. Finally, radiographic progression was assessed using the McNemar test. <h3>Results</h3> Sixty one SpA patients were radiographicaly evaluated at baseline and after 11 (1.7) years of follow-up. A complete radiographic study was recorded in 38 of them. The baseline characteristics, including BASRI values, as well as the treatment received are listed in table 1. The strength of the interobserver concordance in the radiographic analysis was considerable in hips (k=0.77, p&lt;0.001) and almost perfect at the levels of the cervical spine (k=0.88, p&lt;0.001), lumbar spine (k=0.87, p&lt;0.001) and sacroiliac joints (k=0.84, p&lt;0.001). The BASRIs and BASRIt scores were 7.5 (2.9) and 8.8 (4.1) respectively. Moreover, during the follow-up, the BASRIt was increased in 1.23 (p=0.014). Individual analysis of the different components of BASRI, showed that 42.1% of SpA patients got worse regarding the score corresponding to the cervical spine (p&lt;0.001), 28.9% to the lumbar spine (p=0.057), 15.8% to the hip (p=0.754) and no worsening was found in sacroiliac (p=0.500). <h3>Conclusions</h3> This study provides information related to the structural progression of patients followed in a monographic consultation of SpA after 13 years of follow-up. Radiographic evolution was significantly noticed in relation to the total score of the BASRI. However, analysing the individual scores it seems that the cervical spine was the segment where there was greater radiographic progression. We did not find worsening of BASRI in sacroiliac due to the fact that the most of patients already had an advanced degree of sacroileitis in the first visit of the registry. <h3>Disclosure of Interest</h3> None declared
Accuracy and clinical utility of in vitro cytometric profiling to personalize chemotherapy: Preliminary findings of a systematic review and meta-analysis.
Authors: Christian Apfel, Kimberly Souza, Cyrill Hornuss, Larry Weisenthal, Robert Alan Nagourney
Journal: Journal of Clinical Oncology (2013)

e22188 Background: Cytometric analysis, or in-vitro functional profiling, has been developed as a method to predict tumor response to different drugs with the premise to personalize chemotherapy and improve patient outcomes. Methods: We performed a systematic review and a meta-analysis a) of correlative studies using cytometric profiling that reported diagnostic accuracy (sensitivity and specificity) and b) of effectiveness studies comparing patient outcomes when allocated to treatment guided by a cytometric assay versus population-based standard of care. We used Meta-DiSc software to find pooled sensitivity and specificity and analyze the summary receiver operating characteristic (sROC) curve and used Review Manager 5.1 to generate forest plots on overall tumor response (50% or greater decrease in tumor diameter) and on 1-year overall survival. Results: We included 28 mostly retrospective trials (n=664) reporting accuracy data and 15 prospective trials (n=1917) reporting therapeutic efficacy data. The accuracy of correlative study revealed an overall sensitivity of 0.922 (95% confidence interval 0.888 to 0.948), specificity of 0.724 (95% CI 0.669 to 0.774) and an area under the sROC curve of 0.893 (SE=0.023, p&lt;0.001). Studies comparing the clinical utility revealed a two-fold overall tumor response for an assay-guided therapy versus standard of care therapy (odds ratio 2.04, 95% CI 1.62 to 2.57, p&lt;0.001). Similarly, patients who received assay-guided therapy compared to those who received standard of care or physician’s choice had a significantly higher 1-year survival rate (OR 1.44, 95% CI 1.06 to 1.95, p=0.02). Conclusions: Despite various limitations of individual studies, the aggregate and fairly consistent evidence of these data suggests cytometric profiling to be accurate, to improve overall tumor response, and to increase 1-year patient survival. Given the enormous potential for our society, a well-designed and sufficiently-powered randomized controlled trial is urgently needed to validate these results.
Second Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Authors: Carmen Martinez, Ariane Boumendil, Joanna Romejko-Jarosinska, Achilles Anagnostopoulos, Edgar Faber, Xavier Poire, Ibrahim Yakoub-Agha, Saad Akhtar, Gunhan Gurman, Vincenzo Pavone, Kazimierz Halaburda, Aida Botelho Sousa, Herv Ghesquieres, Hervé Finel, Irma Khvedelidze, Silvia Montoto, Anna Sureda
Journal: Blood (2018)
Cardiovascular Function Phenotypes in Response to Cardiotoxic Breast Cancer Therapy
Authors: Biniyam G. Demissei, Brian S. Finkelman, Rebecca A. Hubbard, Amanda M. Smith, Hari K. Narayan, Vivek Narayan, Payal Shah, Adam J. Waxman, Susan M. Domchek, Bonnie Ky
Journal: Journal of the American College of Cardiology (2019)
Abstract P065: Cross-Sectional and Prospective Associations of the Cortisol/testosterone and Cortisol/ Sex Hormone Binding Globulin Ratios With Atherosclerosis in Women
Authors: Ju-Mi Lee, Laura A Colangelo, Joseph E Schwartz, Yuichiro Yano, David S Siscovick, Teresa Seeman, Pamela J Schreiner, Kiang J Liu, Donald M Lloyd-Jones, Philip Philip
Journal: Circulation (2015)

Introduction: The ability to study chronic stress in humans is complicated due to measurement error of questionnaires and the inability of short-term measures of stress hormones to reflect the chronic state. Therefore considerable controversy remains about whether chronic stress influences atherosclerosis or not. The cortisol/testosterone (C/T) ratio was suggested to be a better predictor of heart disease in men than cortisol alone, as gonadotropin and cortisol are derived from the same biochemical precursor. This ratio has never been studied in a U.S. epidemiologic study, especially in women. Study question: Are C/T and C/sex hormone binding globulin (SHBG) ratio associated with subclinical atherosclerosis in women? Methods: In the Coronary Artery Risk Development in Young Adults (CARDIA) study, 367 women (age range 32 to 51, mean age 40 years old) who had both cortisol from year (Y) 15 and sex hormones from serum specimen Y16 measured are included. Intima-media thickness (IMT) from Y20 was assessed cross-sectionally. Coronary artery calcium (CAC) incidence from Y15-25 was assessed prospectively where available (n=299). Due to the instability and diurnal characteristics of cortisol, area under the curve (AUC) of six samples and slope of 1st (or 3rd) and 6th (or 5th when 6th is not available) sample of salivary cortisol collected over one day were calculated. Ratios of AUC and of slope of cortisol to total testosterone (TT), free testosterone (FT), and sex hormone binding globulin (SHBG) were computed: AUC/TT, AUC/FT, AUC/SHBG, Slope/TT, Slope/FT, and Slope/SHBG. The associations of these variables categorized into tertiles with CAC and IMT were assessed by logistic regression analysis (CAC) and multiple linear regression (IMT). Model I controlled for age and race. Model II controlled for model I variables plus BMI, systolic BP, menopause, oral contraceptive usage, diabetes mellitus, alcohol consumption, and cigarette smoking. Results: The highest tertile of AUC/FT ratio was associated with Y20 carotid bulb IMT max in model I (β=0.07, p=0.031) and model II (β=0.09, p=0.006). This ratio also had moderate OR with incident CAC from Y15 to Y25 in model I (OR 2.22, 95% CI 0.89-5.51) and had significant association in model II (OR 3.45, 95% CI 1.18-10.06). Conclusions: Findings suggest that AUC/FT ratio is cross-sectionally and prospectively associated with subclinical atherosclerosis in women.
AB0888 Platelet count in ankylosing spondylitis: can it show the disease activity ?
Authors: S. Rahmouni, M. Slouma, R. Dhahri, L. Metoui, N. Boussetta, N. Gueddiche, F. Laajili, I. Gharsallah, B. Louzir
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are the main inflammatory biomarkers used in assessment of disease activity in numerous inflammatory diseases such as ankylosing spondylitis (SA). In recent years, it has been shown that Platelet count (PC) provided additional information on inflammatory status. <h3>Objectives</h3> The present study aimed to investigate the correlation between PC and clinical activity indices assessed by Bath ankylosing spondylitis disease activity index (BASDAI) <h3>Methods</h3> The study included 68 patients who fulfilled Assessment of Spondyloarthritis International Society Criteria. A cell blood count, including platelet count, ESR (mm/h), CRP (mg/L) and albumin (g/L), was obtained for each patient. Disease activity measures at the time of blood sampling were obtained using the BASDAI. Statistical Package for Social Sciences (SPSS) was used for analysis. <h3>Results</h3> Of the 68 patients, 73.5% were male (Sex Ratio: 2.7). The mean age was 36±12.9 years. The mean disease duration was 40 months [0–192]. The average age of the onset of the disease was 36.6±11.9 years. No patient had ongoing infection at time of study. The mean BASDAI score was 5.1 [1.55–9.2]. Forty-one% of our patients (n=28) had active AS (BASDAI &gt;4) The mean ESR, CRP, albumin and PC were 39.4 (mm/h), 34.1(mg/dL), 39,32 g/L and 311 (10<sup>3</sup>/mL), respectively. There was a positive correlation between platelet count and following biomarkers: ESR (r: −0.481; p: 0.000), CRP (r: 0.417; p: 0.000) and albumin levels (r: −0.556; p:0.000). A negative correlation between and Haemoglobin (Hg) was noted (r: −0.643; p: 0.000). There was no significant difference in laboratory parameters (ESR, CRP, albumin, PC, Hg) between patients with active AS (BASDAI &gt;4) and those with inactive AS (BASDI &lt;4) patients. <h3>Conclusions</h3> Although acute phase reactant such as ESR, CRP and PC mirror disease activity in AS,<sup>1</sup> their values were not associated with disease activity assessed by BASDAI in our study. However, new prospective studies including larger study groups are required to verify the findings of the present study. <h3>Reference</h3> [1] Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol1999;26:966e70. <h3>Disclosure of Interest</h3> None declared
Abstract P360: 24-hour Blood Pressure Profiles Associated With Sleep Duration
Authors: Michael Grandner, Debbie L Cohen, Raymond R Townsend
Journal: Circulation (2017)

Introduction: Insufficient sleep is associated incident hypertension. Because blood pressure (BP) varies across 24h, shorter sleep may be associated with increased BP across all 24h. Additionally, we evaluated whether BP variability was also associated with shorter sleep. Methods: Participants were adults with untreated prehypertension or stage-1 hypertension assessed at baseline as part of a clinical trial. Recordings took place during overnight visits in a Clinical Research Center. Sleep was reported by nurses continuously monitoring patients. Those with &lt;7h sleep were classified “shorter” (N=13) and the rest “longer” (N=30). BP was assessed with a Spacelabs ambulatory monitor. Linear regression models evaluated effect of group on day, night, and 24h systolic and diastolic BP and heart rate (HR). Results: The “shorter” group slept for M=370 (SD=87) minutes and the “longer” group slept for M=521 (SD=51) mins. Results for day, night, and 24h systolic and diastolic blood pressure and heart rate are reported in the Table. Also, higher 24h variability in systolic BP (B=1.2, p=0.03), diastolic BP (B=1.4, p=0.002), and HR (B=1.3, p=0.03) were demonstrated. This was reflected in higher variability during daytime for systolic BP (B=1.1, p=0.04), diastolic BP (B=1.5, p=0.001), and HR (B=1.2, p=0.05); no differences in variability were seen during the night. Conclusions: Shorter sleep duration is associated with higher systolic BP and HR across 24h (day and night), as well as increased variability in systolic and diastolic BP and HR across 24h (during the day in particular). This could provide additional insight in to how sleep duration is associated with hypertension incidence.
FRI0243 Anakinra for calcium pyrophosphate crystal arthritis: an efficient, safe alternative treatment
Authors: M. Thomas, M. FORIEN, E. PALAZZO, P. DIEUDÉ, S. OTTAVIANI
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Calcium pyrophosphate (CPP) deposition is a frequent joint disease with increased prevalence in older people in whom treatment of acute CPP arthritis with conventional therapies such as colchicine, corticosteroids or non-steroidal anti-inflammatory drugs (NSAIDs) could be contraindicated or not used at an optimal dose. As recommended in gout, anakinra might represent an alternative treatment for acute arthritis. In contrast, the relevance of anakinra in acute CPP arthritis has not given much attention. <h3>Objectives</h3> We further aimed to analyse the efficacy and safety of anakinra in acute CPP arthritis in a large cohort. <h3>Methods</h3> We retrospectively included all patients receiving anakinra for acute CPP arthritis between January 2011 and 2017. Medical history data were collected including hypertension, diabetes mellitus, cardiovascular disease, history of gastroduodenal ulcer, renal impairment and concomitant treatments including anticoagulants or antiplatelet drugs. The following data were collected before and 4 days after the first anakinra injection: swollen joint count (SJC), tender joint count (TJC), pain score on a visual analogue scale (VAS, 0–100 mm) and C-reactive protein (CRP) level. A good response was defined according the evaluation of the physician or documentation in the chart of the phrase "good response" after anakinra treatment. <h3>Results</h3> We included 33 patients (24 women; mean age 79.2±12.8 years). Mean duration of acute arthritis 13.2±12.9 days. CPP arthritis was confirmed by the presence of CCP crystals in synovial fluid in 28/33 (84.8%) patients. For the remaining 5 patients, the diagnosis was confirmed by CPP deposition features seen on imaging. Corticosteroids, NSAIDs and colchicine were previous treatments, without significant improvement in 12 (36.4%), 7 (21.2%) and 18 (54.5%) patients, respectively. The mean dose of corticosteroids was 20.8±8.2 mg/day. Among the 33 patients, 32 had a documented visit at day 4. The number of good responders was 27 (81.8%). At day 4, patients showed decreased mean VAS pain score (from 64.8±26.5 to 21.2±19.7 mm, p&lt;0.0001), TJC (5.8±5.0 to 1.0±1.0, p&lt;0.0001), SJC (3.9±2.7 to 0.9±1.0, p&lt;0.0001) and CRP level (116.1±71.6 to 26.0±23.1 mg/L, p&lt;0.0001). Anakinra was well tolerated. Only one patient had pneumonitis that was resolved with oral antibacterial agents. <h3>Conclusions</h3> Our results suggest that anakinra could be a relevant alternative for managing acute CPP arthritis, leading to rapid relief of inflammatory symptoms, with a good tolerance. <h3>Disclosure of Interest</h3> None declared